Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures of clinical effectiveness and cost-effectiveness, that new interventions for sickle cell disease will differentially benefit an historically disadvantaged and underserved community.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for sickle cell disease, including crizanlizumab (Adakveo, Novartis), voxelotor (Oxbryta, Global Blood Therapeutics), and L-glutamine (Endari, Emmaus Life Sciences).
This preliminary draft marks the midpoint of ICER’s eight-month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
